BioMimetic sees FDA panel detractors for bone graft system

05/12/2011 | Wall Street Journal, The

An FDA advisory panel narrowly recommended the approval of BioMimetic Therapeutics' Augment bone graft system, which is designed for use in foot and ankle fusion surgeries. Meanwhile, BioMimetic officials responded to a negative review by FDA staff, saying there "was absolutely no data" to indicate that its device causes cancer.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN